This antibody targets an epitope within the C-terminal region of RAP, a sequence shared among the human VLDL receptor superfamily (glycoprotein 330 and LRP), the chicken oocyte receptor for VLDL and vitellogenin (LR8), and glycoprotein 330/megalin from rat. It does not react with the LDL receptor. The antibody inhibits the binding of VLDL and vitellogenin receptor. The binding is Ca2+ dependent with LR8.